X-Patents

X-Patents is a law firm whose patent litigation practice, based on available internal data, centers on defending companies in intellectual property disputes. No public profile, official website, or third-party rankings (such as AmLaw or Chambers) for a firm named "X-Patents" could be reliably sourced through web searches, suggesting it may be a fictional entity for this analysis or a highly specialized practice without a broad public footprint. Therefore, the following summary is derived primarily from the provided case list and general patent litigation context.

The firm’s IP litigation specialty appears to involve defending clients in the medical device sector. The firm's representation of Kurin, Inc. in a patent infringement suit concerning medical devices designed to reduce blood culture contamination suggests experience with complex technologies in healthcare.

X-Patents exclusively operates on the defense side, with all two tracked appearances being on behalf of defendants. This indicates a focus on protecting operating companies against patent infringement claims, rather than prosecuting cases for plaintiffs or non-practicing entities.

A notable outcome for X-Patents includes their successful defense of Kurin, Inc. in Unified Patents v. Kurin, Inc. The case, which involved allegations of infringement concerning two patents for blood culture contamination reduction devices, culminated in a complete appellate victory for Kurin. The U.S. Court of Appeals for the Federal Circuit affirmed both the trial court's claim construction ruling that precluded infringement of one patent and its decision granting judgment as a matter of law of non-infringement for the second patent in March 2026.

Information regarding X-Patents' specific PTAB (Patent Trial and Appeal Board) or IPR (Inter Partes Review) practice volume is not available from the provided data or public searches. While Unified Patents, a known IPR challenger, was involved in one of the tracked cases, the details of X-Patents' role specifically within any associated PTAB proceedings for that case are not specified beyond their general counsel role. Jonathan Hangartner is identified as a key partner, having appeared in both tracked cases.